Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Department of Community Mental Health, University of Haifa, Haifa, Israel.
BMJ. 2018 Jun 8;361:k2233. doi: 10.1136/bmj.k2233.
To examine the association between paternal antidepressant use at conception and offspring preterm birth, malformations, autism spectrum disorder, and intellectual disability.
Observational prospective cohort study with regression methods, and negative control comparison.
Sweden nationwide.
170 508 children conceived from 29 July 2005 and born in 2006-07, followed up to 2014 at age 8-9 years. This cohort included 3983 children born to fathers receiving antidepressant treatment during the conception period (that is, from four weeks before conception to four weeks after), a control group of 164 492 children not exposed to paternal antidepressant use, and a negative control comparison group of 2033 children born to fathers who did not use antidepressants during the conception period but began antidepressant treatment later during the pregnancy period (that is, from four weeks after conception to childbirth).
Offspring preterm birth, malformation diagnosed at birth, diagnosis of autism spectrum disorder, and diagnosis of intellectual disability.
Paternal antidepressant use during conception was not associated with preterm birth (adjusted odds ratio 0.91 (95% confidence interval 0.79 to 1.04)) or malformations (1.06 (0.90 to 1.26)) using logistic regression, compared with offspring born to unexposed fathers. No association was seen between antidepressant use during conception and autism (adjusted hazard ratio 1.13 (0.84 to 1.53)) or intellectual disability (0.82 (0.51 to 1.31)) using Cox regression. In children whose fathers initiated antidepressant treatment during pregnancy, results were similar for all outcomes apart from intellectual disability, which had an increased adjusted hazard ratio (1.66 (1.06 to 2.59)). Compared with the 2033 children whose fathers initiated antidepressant treatment during pregnancy, the 3983 children exposed to paternal use of antidepressants at conception had no differences in preterm birth, malformation, and autism, but a reduced risk of intellectual disability (adjusted hazard ratio 0.49 (0.26 to 0.93)).
Paternal intake of antidepressants during the period around conception is safe with respect to the risk of the four major adverse outcomes in offspring-preterm birth, malformation, autism, or intellectual disability.
研究父亲在受孕时使用抗抑郁药与后代早产、畸形、自闭症谱系障碍和智力残疾之间的关联。
具有回归方法和负对照比较的观察性前瞻性队列研究。
瑞典全国。
170508 名于 2005 年 7 月 29 日受孕并于 2006-07 年出生的儿童,随访至 2014 年 8-9 岁。该队列包括 3983 名在受孕期间接受抗抑郁药物治疗的父亲所生的儿童(即从受孕前四周到受孕后四周),一个对照组包括 164492 名未接触到父亲使用抗抑郁药物的儿童,以及一个负对照组,包括 2033 名在受孕期间未使用抗抑郁药物但在孕期后期开始使用抗抑郁药物的父亲所生的儿童(即从受孕后四周到分娩)。
后代早产、出生时诊断出的畸形、自闭症谱系障碍的诊断和智力残疾的诊断。
与未暴露于父亲的抗抑郁药的子女相比,父亲在受孕期间使用抗抑郁药与早产(调整后的优势比 0.91(95%置信区间 0.79 至 1.04))或畸形(1.06(0.90 至 1.26))无关。使用 Cox 回归,在受孕期间使用抗抑郁药与自闭症(调整后的危害比 1.13(0.84 至 1.53))或智力残疾(0.82(0.51 至 1.31))之间也没有关联。在父亲在孕期开始使用抗抑郁药物的儿童中,除了智力残疾外,所有结果的结果相似,智力残疾的调整后危害比增加(1.66(1.06 至 2.59))。与 2033 名父亲在孕期开始使用抗抑郁药物的儿童相比,3983 名在受孕时接触到父亲使用抗抑郁药物的儿童在早产、畸形和自闭症方面没有差异,但智力残疾的风险降低(调整后的危害比 0.49(0.26 至 0.93))。
父亲在受孕前后期间摄入抗抑郁药与后代早产、畸形、自闭症或智力残疾的四大主要不良结局风险无关。